drugset / Trial / NCT03735316

Vitamin B12a Vasoplegic Syndrome

NCT03735316

Phase 2 Terminated 8 enrolled Mayo Clinic
RandomizedParallel-groupTriple-blindSupportive care

Summary

The study team will evaluate the medication Hydroxocobalamin (B12a) for treatment of low blood pressure after cardiac surgery.

Timeline

Start
2019-04-25
Primary completion
2022-04-01
Completion
2022-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxocobalamin Unknown 5 g Intravenous

Indications

No indication recorded.